Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- City of Hope South Pasadena
South Pasadena, California, United States
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Moffitt Cancer Center-International Plaza
Tampa, Florida, United States
- Northside Hospital
Atlanta, Georgia, United States
- Eastern Maine Medical Center
Bangor, Maine, United States
- Lafayette Family Cancer Center-Emmc
Brewer, Maine, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 May 2013
- Primary completion
- 31 Dec 2018
- Completion
- 10 Jun 2021
- Last update posted
- 24 Jun 2021
- Registered enrollment
- 71
- Registry id
- NCT01822509
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.